Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to
treat IPF. On the other hand, the placebo arms of these large trials have provided us with …

STUDY OBJECTIVE: To compare the survival of patients with IPF treated retrospectively with
corticosteroids alone, to survival of patients treated with immunosuppressive and …

Purpose In patients with idiopathic pulmonary fibrosis (IPF), hospitalizations are associated
with high mortality. We sought to determine in-hospital mortality rates and factors associated …

Background Little is known about generalisability of randomised controlled trials (RCTs) for
idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to …

Results A total of 82,702 deaths were attributed to IPF-CS in England and Wales from 1979
to 2016. The overall age-standardized mortality rate for this period was 4.68 per 100,000 …

Rationale Longitudinal data on the impact of continued, switched or discontinued antifibrotic
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Placebo arms of clinical trials provide an opportunity to investigate the natural history of
idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fibrosing lung disease with a poor
prognosis. Between 60% and 70% of IPF patients die of IPF; the remaining causes of death …